Pancreatic Adenocarcinoma Clinical Trials in New Brunswick, New Jersey

4 studies are recruiting for pancreatic adenocarcinoma in New Brunswick, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

    Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tel…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    46 in total
    Run by
    Astellas Pharma Global Development, Inc.

    See if you can join NCT05365581 on ClinicalTrials.gov

  2. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rutgers Cancer University, New Brunswick, New Jersey
    Locations
    9 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07621718 on ClinicalTrials.gov

  3. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
    Locations
    25 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

  4. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, New Brunswick, New Jersey
    Locations
    23 in total
    Run by
    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.